13 september 2022: ESMO 2022

Afgelopen week was er ESMO 2022. Hier een aantal aanbevolen abstracten door vooraanstaande oncologen gerelateerd aan spijsverteringskanker waaronder darmkanker, maagkanker, leverkanker en slokdarmkanker.

De aanbevolen abstracten staan onder elkaar in dit artikel. Als u naar ESMO 2022 gaat kunt u via de nummers van de abstracten deze vinden.

Aanbevolen abstracten door Jun Gong MD 

Saturday, September 10, 2022
8:30–9:50 CEST; Proffered Paper Session
GI, Upper Digestive

LBA34 Primary results from the phase 3 LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). RS Finn

Sunday, September 11, 2022
10:15–11:45 CEST; Proffered Paper Session 1
GI, Lower Digestive

314O Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): a randomized,phase 3 study. A Arjona

Sunday, September 11, 2022
16:30–18:15 CEST; Proffered Paper Session
Presidential Symposium II

LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. M Chalabi

Monday, September 12, 2022
10:15–11:45 CEST; Proffered Paper Session 2
GI, Lower Digestive

LBA24 KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation. SJ Klempner

LBA25 FRESCO-2: A global phase 3 multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. NA Dasari

315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: safety and efficacy for phase 1b full expansion cohort. Y Kuboki

Monday, September 12, 2022
14:45–15:55 CEST; Mini Oral Session
GI, Lower Digestive

LBA27 Additional analyses of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC. JH Strickler

318MO Circulating Tumour DNA (ctDNA) Dynamics, CEA and Sites of Recurrence for the Randomised DYNAMIC Study: Adjuvant Chemotherapy (ACT) Guided by ctDNA Analysis in Stage II Colon Cancer (CC). J Tie

319MO Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer. SA Cohen

320MO A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC). MG Faki

Plaats een reactie ...

Reageer op "ESMO 2022. Aanbevolen abstracten gerelateerd aan spijsverteringskanker waaronder darmkanker, maagkanker, leverkanker en slokdarmkanker door vooraanstaande oncologen"

Gerelateerde artikelen

Gerelateerde artikelen

Personalised medicin en gerichte >> Studiepublicaties van niet-toxische >> UEG oktober 2020: Abstracten >> ESMO 2023: aanbevolen abstracten >> ASCO 2023: aanbevolen abstracten >> Aanvullende niet toxische >> Adagrasib met of zonder cetuximab >> Aflibercept (Zaltrap) toegevoegd >> Avastin - bevacizumab de >> Bestraling - radiotherapie >>